V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220021697 | 220005295 | 1.56 | 78 | Curative (C) | 2018-08-07 | 2019-01-15 | AML Interim Guidelines FLAG-Ida | N | N | 220020551 | FLAG + IDARUBICIN |
| 220021698 | 220012787 | 1.72 | null | Curative (C) | 2017-02-12 | 2017-05-15 | AML17 TRIAL | N | N | 220020576 | AML17 TRIAL |
| 220021699 | 220005315 | 1.75 | 64.5 | Palliative (P) | 2014-03-26 | 2014-03-26 | AML17 TRIAL | N | N | 220020591 | AML17 TRIAL |
| 220021700 | 220005332 | 0 | 73 | Adjuvant (A) | 2013-11-24 | 2013-12-01 | AML17 TRIAL | Y | N | 220020646 | AML17 TRIAL |
| 220021701 | 220012808 | 1.7 | 70 | null | 2017-10-26 | 2018-01-29 | AML17 TRIAL | N | N | 220020649 | AML17 TRIAL |
| 220021702 | 220019362 | 1.73 | 51.4 | Curative (C) | 2014-04-18 | 2014-07-11 | AML Interim Guidelines FLAG-Ida | Y | N | 220020654 | FLAG + IDARUBICIN |
| 220021703 | 220005352 | 1.76 | null | Adjuvant (A) | 2019-04-23 | 2019-04-23 | AML17 TRIAL | null | N | 220020673 | AML17 TRIAL |
| 220021704 | 220005360 | 1.7 | 87 | Curative (C) | 2014-04-16 | 2015-10-02 | AML17 TRIAL | N | N | 220020676 | AML17 TRIAL |
| 220021705 | 220005368 | 1.87 | 74.9 | Disease modification (D) | 2020-04-01 | 2020-07-08 | FLAG + Idarubicin | N | null | 220020695 | FLAG + IDARUBICIN |
| 220021706 | 220005389 | 1.61 | 53.1 | Disease modification (D) | 2017-03-19 | 2017-08-19 | FLAG + Idarubicin | 02 | N | 220020746 | FLAG + IDARUBICIN |
| 220021708 | 220005464 | 1.76 | 82.3 | Curative (C) | 2017-09-27 | 2017-10-01 | FLAG + Idarubicin | 01 | N | 220020990 | FLAG + IDARUBICIN |
| 220021710 | 220005510 | 1.85 | 108.4 | Curative (C) | 2019-03-25 | 2019-03-26 | AML17 TRIAL | Y | N | 220021137 | AML17 TRIAL |
| 220021711 | 220005523 | 1.69 | 78.1 | Curative (C) | 2018-04-29 | 2018-07-31 | FLAG + Idarubicin | N | N | 220021161 | FLAG + IDARUBICIN |
| 220021712 | 220005533 | 1.65 | 65.1 | Curative (C) | 2014-03-24 | 2014-03-24 | AML 19 TRIAL | N | null | 220021175 | AML19 TRIAL |
| 220021713 | 220005556 | 1.79 | 99.4 | Disease modification (D) | 1536-03-07 | 1536-03-08 | Trial Unspecified | 02 | N | 220021255 | TRIAL |
| 220021714 | 220012943 | 1.7 | 94.3 | Curative (C) | 2018-03-31 | 2018-04-04 | Trial Unspecified | 2 | N | 220021359 | TRIAL |
| 220021715 | 220005603 | 0 | 85.2 | Curative (C) | 2018-02-24 | 2018-05-04 | AML 19 TRIAL | N | N | 220021394 | AML19 TRIAL |
| 220021716 | 220005607 | 1.72 | 68.7 | Curative (C) | 2014-07-19 | 2017-02-18 | AML 19 TRIAL | Y | N | 220021411 | AML19 TRIAL |
| 220021717 | 220019406 | 1.49 | 98 | Curative (C) | 2016-02-20 | 2016-02-21 | AML 19 TRIAL | N | N | 220021453 | AML19 TRIAL |
| 220021718 | 220005634 | 1.87 | 63.9 | Disease modification (D) | 2019-04-07 | 2019-05-28 | AML 19 TRIAL | Y | N | 220021470 | AML19 TRIAL |
| 220021719 | 220005645 | 1.6 | 81.15 | Curative (C) | 2018-01-04 | 2018-03-25 | AML 19 TRIAL | N | N | 220021483 | AML19 TRIAL |
| 220021720 | 220017130 | 1.62 | 53.4 | Curative (C) | 2018-10-19 | 2018-10-19 | Trial Unspecified | 01 | N | 220021572 | TRIAL |
| 220021722 | 220012999 | null | 69.4 | Curative (C) | 2018-07-09 | 2018-07-09 | AML 19 TRIAL | 01 | N | 220021673 | AML19 TRIAL |
| 220021723 | 220020698 | 1.68 | 58.3 | Curative (C) | 2017-06-12 | 2017-10-01 | AML 19 TRIAL | Y | N | 220021690 | AML19 TRIAL |
| 220021724 | 220005722 | 1.56 | null | Curative (C) | null | 2018-12-17 | Trial Unspecified | 1 | N | 220021705 | TRIAL |
| 220021725 | 220005726 | 1.8 | 83 | Curative (C) | 2018-08-19 | 2018-11-27 | Trial Unspecified | Y | N | 220021721 | TRIAL |
| 220021726 | 220005760 | 1.72 | 74.6 | Curative (C) | 2017-08-19 | 2017-08-19 | Trial Unspecified | Y | N | 220021789 | TRIAL |
| 220021727 | 220013035 | 1.85 | 85.4 | Curative (C) | 2015-04-24 | 2015-05-05 | AML 19 TRIAL | Y | null | 220021792 | AML19 TRIAL |
| 220021728 | 220005772 | 1.66 | 107.5 | null | 2015-12-25 | 2015-12-25 | Trial Unspecified | Y | N | 220021810 | TRIAL |
| 220021730 | 220005808 | 1.94 | 71.4 | Curative (C) | 2019-04-26 | 2019-04-26 | Trial Unspecified | N | N | 220021942 | TRIAL |
| 220021731 | 220005820 | 1.77 | 99.6 | Disease modification (D) | 2014-04-11 | 2014-05-19 | AML 19 TRIAL | 01 | N | 220021958 | AML19 TRIAL |
| 220021732 | 220005825 | 1.49 | 107.5 | Disease modification (D) | 2014-02-12 | 2014-03-12 | Trial Unspecified | Y | N | 220021966 | TRIAL |
| 220021733 | 220005833 | 1.57 | 89.5 | Disease modification (D) | 2016-08-12 | 2016-08-17 | Trial Unspecified | Y | N | 220021995 | TRIAL |
| 220021734 | 220013101 | 1.73 | 84 | Curative (C) | 2016-07-10 | 2016-09-10 | AML 19 TRIAL | 01 | N | 220022059 | AML19 TRIAL |
| 220021735 | 220013105 | 1.69 | 62 | Curative (C) | 2016-06-18 | 2016-06-19 | AML 19 TRIAL | 1 | N | 220022092 | AML19 TRIAL |
| 220021736 | 220005872 | 1.72 | 74.8 | Curative (C) | 2014-11-21 | 2014-11-29 | AML 19 TRIAL | 1 | N | 220022122 | AML19 TRIAL |
| 220021737 | 220005879 | 1.78 | 76.1 | null | 2013-09-19 | 2013-09-22 | Trial Unspecified | Y | N | 220022138 | TRIAL |
| 220021738 | 220005887 | null | 58.8 | Curative (C) | 2014-05-08 | 2014-06-08 | AML 19 TRIAL | Y | N | 220022174 | AML19 TRIAL |
| 220021739 | 220005901 | 1.79 | 72.1 | Adjuvant (A) | 2014-07-17 | 2014-10-16 | AML 19 TRIAL | null | N | 220022212 | AML19 TRIAL |
| 220021740 | 220013166 | 1.56 | 63.4 | Curative (C) | 2016-06-04 | 2016-06-06 | AML 19 TRIAL | 01 | null | 220022379 | AML19 TRIAL |
| 220021741 | 220005969 | 1.72 | 68 | null | 2019-04-18 | 2019-04-18 | Cytarabine Low Dose | N | N | 220022475 | CYTARABINE |
| 220021742 | 220005974 | null | null | Palliative (P) | 2018-03-13 | 2018-03-17 | Hydroxycarbamide | 2 | N | 220022478 | HYDROXYCARBAMIDE |
| 220021743 | 220005992 | 1.52 | 0 | Palliative (P) | 2013-08-30 | 2014-12-15 | Hydroxycarbamide | 2 | N | 220022570 | HYDROXYCARBAMIDE |
| 220021744 | 220005993 | 1.56 | 67 | Adjuvant (A) | null | 2015-06-27 | Cytarabine Low Dose | Y | N | 220022576 | CYTARABINE |
| 220021745 | 220017221 | 1.6 | 46.2 | Curative (C) | 2019-05-02 | 2019-06-03 | Amsacrine + ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) + BUSULFAN + CYTARABINE + FLUDARABINE | N | N | 220022595 | NOT MATCHED |
| 220021746 | 220006013 | 1.61 | 74 | Disease modification (D) | 2014-10-16 | 2015-02-05 | Hydroxycarbamide | 2 | Y | 220022645 | HYDROXYCARBAMIDE |
| 220021747 | 220013212 | 0 | null | Palliative (P) | 2014-03-09 | 2014-03-26 | Hydroxycarbamide | 2 | N | 220022679 | HYDROXYCARBAMIDE |
| 220021749 | 220006026 | null | 12.8 | Curative (C) | 2014-07-14 | 2014-08-21 | Amsacrine + BUSULFAN + CYTARABINE + FLUDARABINE | 99 | null | 220022722 | NOT MATCHED |
| 220021750 | 220006047 | 1.79 | 62.8 | Disease modification (D) | 2013-10-30 | 2014-02-13 | Hydroxycarbamide | 02 | N | 220022807 | HYDROXYCARBAMIDE |
| 220021751 | 220006050 | 1.8 | 103 | Palliative (P) | null | 2017-03-24 | Hydroxycarbamide | N | N | 220022827 | HYDROXYCARBAMIDE |